世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

NA非ホジキンリンパ腫診断薬市場 - 2030年までの産業動向と予測


NA Non-Hodgkin Lymphoma Diagnostics Market - Industry Trends and Forecast to 2030

北米の非ホジキンリンパ腫診断市場は、2023年から2030年の予測期間に9.1%の大幅なCAGRを記録すると予測される。この新しい市場レポートは、歴史的年2021年のデータを含み、計算の基準年は2022年、予測期間は2023... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
Data Bridge Market Research
データブリッジマーケットリサーチ 		2023年4月1日 US$3,500
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら 		293 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

北米の非ホジキンリンパ腫診断市場は、2023年から2030年の予測期間に9.1%の大幅なCAGRを記録すると予測される。この新しい市場レポートは、歴史的年2021年のデータを含み、計算の基準年は2022年、予測期間は2023年から2030年です。

市場細分化：
北米の非ホジキンリンパ腫診断市場：検査タイプ別（画像診断、生検、免疫組織化学、バイオマーカー検査、遺伝子検査、細胞遺伝学、腰椎穿刺（脊髄穿刺）、血液検査、細胞化学）、がんステージ別（ステージIV、ステージIII、ステージII、ステージI、ステージ0）、腫瘍タイプ別（悪性リンパ腫、低悪性度リンパ腫）、製品別（機器ベース製品、プラットフォームベース製品、キット・試薬、その他消耗品）、技術（蛍光in situハイブリダイゼーション、次世代シーケンシング、フルオイムノアッセイ、比較ゲノムハイブリダイゼーション、免疫組織化学、その他）、用途（スクリーニング、診断・予測、予後予測、研究）、エンドユーザー（病院、診断センター、がん研究センター、学術機関、外来手術センター、その他）、流通チャネル（直接入札、小売販売、その他）、国（U.S.,国別（米国、カナダ、メキシコ）産業動向と2030年までの予測
北米の非ホジキンリンパ腫診断薬市場の成長に寄与する主な要因には、以下のようなものがある：
- 非ホジキンリンパ腫有病率の増加
- 非ホジキンリンパ腫の診断における人工知能の進歩
市場プレイヤー

北米の非ホジキンリンパ腫診断市場に参入している主な企業は以下の通り：

- キャノンメディカルシステムズ株式会社
- フィリップスN.V.
- シーメンスヘルスケアGmbH
- ダナハー
- バイオ・ラッド・ラボラトリーズ・インク
- ゼネラル・エレクトリック社
- シスメックス株式会社
- グレイル
- F.ホフマン・ラ・ロシュ
- ノイソフトコーポレーション
- アジレント・テクノロジー株式会社
- ネオジェノミクス・ラボラトリーズ
- ホロジック社
- インテグレーテッドDNAテクノロジー社
- セントジェン社
- メリット・メディカル・システムズ
- インビタエ・コーポレーション
- パーキンエルマー社
- QIAGEN
- GeneDx, LLC



ページTOPに戻る


目次

TABLE OF CONTENTS
1 INTRODUCTION 83
1.1 OBJECTIVES OF THE STUDY 83
1.2 MARKET DEFINITION 83
1.3 OVERVIEW OF THE NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET 83
1.4 LIMITATIONS 85
1.5 MARKETS COVERED 86
2 MARKET SEGMENTATION 89
2.1 MARKETS COVERED 89
2.2 GEOGRAPHICAL SCOPE 90
2.3 YEARS CONSIDERED FOR THE STUDY 91
2.4 CURRENCY AND PRICING 91
2.5 DBMR TRIPOD DATA VALIDATION MODEL 92
2.6 MULTIVARIATE MODELLING 95
2.7 PRODUCT TYPE LIFELINE CURVE 95
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 96
2.9 DBMR MARKET POSITION GRID 97
2.10 MARKET APPLICATION COVERAGE GRID 98
2.11 VENDOR SHARE ANALYSIS 99
2.12 SECONDARY SOURCES 100
2.13 ASSUMPTIONS 100
3 EXECUTIVE SUMMARY 101
4 PREMIUM INSIGHTS 104
4.1 PESTEL ANALYSIS 105
4.2 PORTER'S 5 FORCES 106
5 INDUSTRY INSIGHTS 107
6 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, REGULATIONS 108
7 MARKET OVERVIEW 110
7.1 DRIVERS 112
7.1.1 INCREASED GROWTH IN PREVALENCE OF NON-HODGKIN LYMPHOMA 112
7.1.2 INCREASE IN AWARENESS REGARDING NON-HODGKIN LYMPHOMA 112
7.1.3 ADVANCEMENT IN ARTIFICIAL INTELLIGENCE IN DIAGNOSIS OF NON-HODGKIN LYMPHOMA 112
7.1.4 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UP 113
7.2 RESTRAINTS 113
7.2.1 LACK OF AVAILABILITY OF TRAINED AND SKILLED MEDICAL PROFESSIONALS 113
7.2.2 STRINGENT REGULATIONS AND GUIDELINES FOR DIFFERENT TREATMENTS AND DIAGNOSIS 114
7.3 OPPORTUNITIES 115
7.3.1 TECHNICAL ADVANCEMENTS IN CANCER DIAGNOSIS 115
7.3.2 INCREASING HEALTHCARE EXPENDITURE IN CANCER R&D 115
7.3.3 GROWING INITIATIVES BY GOVERNMENT AND KEY PLAYERS 115
7.4 CHALLENGES 116
7.4.1 LACK OF EARLY DIAGNOSTIC AWARENESS AMONG PEOPLE 116
7.4.2 HIGH DIAGNOSTIC COST AND FEAR OF TREATMENT 116
7.4.3 COMMON MISDIAGNOSIS OF NON-HODGKIN LYMPHOMA (NHL) 117
8 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TEST TYPE 118
8.1 OVERVIEW 119
8.2 IMAGING 122
8.2.1 COMPUTED TOMOGRAPHY (CT) 123
8.2.2 CHEST X-RAY 123
8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 123
8.2.4 ULTRASOUND 123
8.2.5 POSITRON EMISSION TOMOGRAPHY (PET) 123
8.3 BIOPSY 123
8.3.1 EXCISIONAL OR INCISIONAL BIOPSY 124
8.3.2 CORE NEEDLE BIOPSY 124
8.4 IMMUNOHISTOCHEMISTRY 124
8.5 BIOMARKER TEST 125
8.5.1 BETA 2-M 126
8.5.2 LDH 126
8.5.3 CA-125 126
8.5.4 TP53 126
8.5.5 NPM1 127
8.5.6 OTHERS 127
8.6 GENETIC TEST 127
8.7 CYTOGENETICS 127
8.8 LUMBAR PUNCTURE (SPINAL TAP) 128
8.9 BLOOD TEST 129
8.10 CYTOCHEMISTRY 129
8.11 OTHERS 130
9 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TUMOR TYPE 131
9.1 OVERVIEW 132
9.2 AGGRESSIVE LYMPHOMAS 134
9.2.1 DIFFUSE LARGE B CELL LYMPHOMA 135
9.2.1.1 INSTRUMENT BASED PRODUCTS 136
9.2.1.2 PLATFORM BASED PRODUCTS 136
9.2.1.3 KITS AND REAGENTS 136
9.2.1.4 OTHER CONSUMABLES 136
9.2.2 ANAPLASTIC LARGE-CELL LYMPHOMA 136
9.2.2.1 INSTRUMENT BASED PRODUCTS 137
9.2.2.2 PLATFORM BASED PRODUCTS 137
9.2.2.3 KITS AND REAGENTS 137
9.2.2.4 OTHER CONSUMABLES 137
9.2.3 MANTLE CELL LYMPHOMA 137
9.2.3.1 INSTRUMENT BASED PRODUCTS 138
9.2.3.2 PLATFORM BASED PRODUCTS 138
9.2.3.3 KITS AND REAGENTS 138
9.2.3.4 OTHER CONSUMABLES 138
9.2.4 PERIPHERAL T-CELL LYMPHOMA 138
9.2.4.1 INSTRUMENT BASED PRODUCTS 139
9.2.4.2 PLATFORM BASED PRODUCTS 139
9.2.4.3 KITS AND REAGENTS 139
9.2.4.4 OTHER CONSUMABLES 139
9.2.5 LYMPHOBLASTIC LYMPHOMA 139
9.2.5.1 INSTRUMENT BASED PRODUCTS 140
9.2.5.2 PLATFORM BASED PRODUCTS 140
9.2.5.3 KITS AND REAGENTS 140
9.2.5.4 OTHER CONSUMABLES 140
9.2.6 BURKITT LYMPHOMA 140
9.2.6.1 INSTRUMENT BASED PRODUCTS 141
9.2.6.2 PLATFORM BASED PRODUCTS 141
9.2.6.3 KITS AND REAGENTS 141
9.2.6.4 OTHER CONSUMABLES 141
9.3 INDOLENT LYMPHOMAS 141
9.3.1 FOLLICULAR LYMPHOMA 142
9.3.1.1 INSTRUMENT BASED PRODUCTS 143
9.3.1.2 PLATFORM BASED PRODUCTS 143
9.3.1.3 KITS AND REAGENTS 143
9.3.1.4 OTHER CONSUMABLES 143
9.3.2 CUTANEOUS T-CELL LYMPHOMA 143
9.3.2.1 INSTRUMENT BASED PRODUCTS 144
9.3.2.2 PLATFORM BASED PRODUCTS 144
9.3.2.3 KITS AND REAGENTS 144
9.3.2.4 OTHER CONSUMABLES 144
9.3.3 MARGINAL ZONE B CELL LYMPHOMA 144
9.3.3.1 INSTRUMENT BASED PRODUCTS 145
9.3.3.2 PLATFORM BASED PRODUCTS 145
9.3.3.3 KITS AND REAGENTS 145
9.3.3.4 OTHER CONSUMABLES 145
9.3.4 LYMPHOPLASMACYTIC LYMPHOMA 145
9.3.4.1 INSTRUMENT BASED PRODUCTS 146
9.3.4.2 PLATFORM BASED PRODUCTS 146
9.3.4.3 KITS AND REAGENTS 146
9.3.4.4 OTHER CONSUMABLES 146
9.3.5 SMALL-CELL LYMPHOCYTIC LYMPHOMA 146
9.3.5.1 INSTRUMENT BASED PRODUCTS 147
9.3.5.2 PLATFORM BASED PRODUCTS 147
9.3.5.3 KITS AND REAGENTS 147
9.3.5.4 OTHER CONSUMABLES 147
10 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY APPLICATION 148
10.1 OVERVIEW 149
10.2 SCREENING 151
10.2.1 INSTRUMENT BASED PRODUCTS 152
10.2.2 PLATFORM BASED PRODUCTS 152
10.2.3 KITS AND REAGENTS 153
10.2.4 OTHER CONSUMABLES 153
10.3 DIAGNOSTIC AND PREDICTIVE 153
10.3.1 INSTRUMENT BASED PRODUCTS 154
10.3.2 PLATFORM BASED PRODUCTS 154
10.3.3 KITS AND REAGENTS 154
10.3.4 OTHER CONSUMABLES 154
10.4 PROGNOSTIC 154
10.4.1 INSTRUMENT BASED PRODUCTS 155
10.4.2 PLATFORM BASED PRODUCTS 155
10.4.3 KITS AND REAGENTS 155
10.4.4 OTHER CONSUMABLES 156
10.5 RESEARCH 156
10.5.1 INSTRUMENT BASED PRODUCTS 157
10.5.2 PLATFORM BASED PRODUCTS 157
10.5.3 KITS AND REAGENTS 157
10.5.4 OTHER CONSUMABLES 157
11 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE 158
11.1 OVERVIEW 159
11.2 STAGE IV 161
11.3 STAGE I 162
11.4 STAGE III 163
11.5 STAGE II 164
11.6 STAGE 0 165
12 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TECHNOLOGY 166
12.1 OVERVIEW 167
12.2 FLUORESCENT IN SITU HYBRIDIZATION 169
12.3 NEXT GENERATION SEQUENCING 170
12.4 FLUORIMMUNOASSAY 171
12.5 COMPARATIVE GENOMIC HYBRIDIZATION 172
12.6 IMMUNOHISTOLOCHEMICAL 172
12.7 OTHER 173
13 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY PRODUCT 174
13.1 OVERVIEW 175
13.2 INSTRUMENT BASED PRODUCTS 177
13.2.1 IMAGING 178
13.2.2 BIOPSY 178
13.3 PLATFORM BASED PRODUCTS 179
13.3.1 NEXT-GENERATION SEQUENCING 180
13.3.2 MICROARRAYS 180
13.3.3 PCR 180
13.3.4 OTHERS 180
13.4 KITS AND REAGENTS 180
13.4.1 NON-HODGKIN LYMPHOMA PANELS 181
13.4.2 IMMUNOHISTOCHEMISTRY STAINS 181
13.4.3 OTHERS 181
13.5 OTHER CONSUMABLES 182
14 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY END USER 183
14.1 OVERVIEW 184
14.2 HOSPITALS 186
14.3 DIAGNOSTIC CENTERS 187
14.4 CANCER RESEARCH CENTERS 188
14.5 ACADEMIC INSTITUTES 189
14.6 AMBULATORY SURGICAL CENTERS 189
14.7 OTHERS 190
15 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 191
15.1 OVERVIEW 192
15.2 DIRECT TENDER 194
15.3 RETAIL SALES 195
15.4 OTHERS 196
16 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION 197
16.1 NORTH AMERICA 198
16.1.1 U.S. 216
16.1.2 CANADA 228
16.1.3 MEXICO 240
17 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 252
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 252
18 SWOT ANALYSIS 253
19 NORTH AMERICA NON-HODKIN LYMPHOMA DIAGNOSTICS MARKET 254
19.1 CANON MEDICAL SYSTEMS CORPORATION 254
19.1.1 COMPANY SNAPSHOT 254
19.1.2 REVENUE ANALYSIS 254
19.1.3 COMPANY SHARE ANALYSIS 255
19.1.4 PRODUCT PORTFOLIO 255
19.1.5 RECENT DEVELOPMENT 255
19.2 KONINKLIJKE PHILIPS N.V. 256
19.2.1 COMPANY SNAPSHOT 256
19.2.2 REVENUE ANALYSIS 256
19.2.3 COMPANY SHARE ANALYSIS 257
19.2.4 PRODUCT PORTFOLIO 257
19.2.5 RECENT DEVELOPMENTS 257
19.3 SIEMENS HEALTHCARE GMBH 258
19.3.1 COMPANY SNAPSHOT 258
19.3.2 REVENUE ANALYSIS 258
19.3.3 COMPANY SHARE ANALYSIS 259
19.3.4 PRODUCT PORTFOLIO 259
19.3.5 RECENT DEVELOPMENT 260
19.4 DANAHER. 261
19.4.1 COMPANY SNAPSHOT 261
19.4.2 REVENUE ANALYSIS 261
19.4.3 COMPANY SHARE ANALYSIS 262
19.4.4 PRODUCT PORTFOLIO 262
19.4.5 RECENT DEVELOPMENTS 263
19.5 BIO-RAD LABORATORIES, INC. 264
19.5.1 COMPANY SNAPSHOT 264
19.5.2 REVENUE ANALYSIS 264
19.5.3 COMPANY SHARE ANALYSIS 265
19.5.4 PRODUCT PORTFOLIO 265
19.5.5 RECENT DEVELOPMENT 265
19.6 AGILENT TECHNOLOGIES, INC. 266
19.6.1 COMPANY PROFILE 266
19.6.2 REVENUE ANALYSIS 266
19.6.3 PRODUCT PORTFOLIO 267
19.6.4 RECENT DEVELOPMENT 267
19.7 CENTOGENE N.V. 268
19.7.1 COMPANY SNAPSHOT 268
19.7.2 PRODUCT PORTFOLIO 268
19.7.3 RECENT DEVELOPMENT 268
19.8 F. HOFFMANN- LA ROCHE LTD 269
19.8.1 COMPANY SNAPSHOT 269
19.8.2 REVENUE ANALYSIS 269
19.8.3 PRODUCT PORTFOLIO 270
19.8.4 RECENT DEVELOPMENTS 270
19.9 GENERAL ELECTRIC COMPANY 271
19.9.1 COMPANY SNAPSHOT 271
19.9.2 REVENUE ANALYSIS 271
19.9.3 PRODUCT PORTFOLIO 272
19.9.4 RECENT DEVELOPMENTS 272

　

ページTOPに戻る


　

Summary

The North America Non-Hodgkin lymphoma diagnostics market is projected to register a substantial CAGR of 9.1% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:
North America Non-Hodgkin Lymphoma Diagnostics Market, By Test Type (Imaging, Biopsy, Immunohistochemistry, Biomarker Test, Genetic Test, Cytogenetics, Lumbar Puncture (Spinal Tap), Blood Test and Cytochemistry), Cancer Stage (Stage IV, Stage III, Stage II, Stage I, and Stage 0), Tumor Type (Aggressive Lymphomas and Indolent Lymphomas), Product (Instrument Based Products, Platform Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the North America Non-Hodgkin lymphoma diagnostics market are:
• Increased growth in the prevalence of Non-Hodgkin Lymphoma
• Advancement in artificial intelligence in the diagnosis of Non-Hodgkin Lymphoma
Market Players:

Some of the major players operating in the North America Non-Hodgkin lymphoma diagnostics market are:

• CANON MEDICAL SYSTEMS CORPORATION
• Koninklijke Philips N.V.
• Siemens Healthcare GmbH
• Danaher.
• Bio-Rad Laboratories, Inc.
• General Electric Company
• Sysmex Corporation
• Grail
• F. Hoffmann-La Roche
• Neusoft Corporation
• Agilent Technologies, Inc.
• NeoGenomics Laboratories
• Hologic, Inc
• Integrated DNA Technologies, Inc.
• CENTOGENE N.V.
• Merit Medical Systems
• Invitae Corporation
• PerkinElmer Inc.
• QIAGEN
• GeneDx, LLC



ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 83
1.1 OBJECTIVES OF THE STUDY 83
1.2 MARKET DEFINITION 83
1.3 OVERVIEW OF THE NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET 83
1.4 LIMITATIONS 85
1.5 MARKETS COVERED 86
2 MARKET SEGMENTATION 89
2.1 MARKETS COVERED 89
2.2 GEOGRAPHICAL SCOPE 90
2.3 YEARS CONSIDERED FOR THE STUDY 91
2.4 CURRENCY AND PRICING 91
2.5 DBMR TRIPOD DATA VALIDATION MODEL 92
2.6 MULTIVARIATE MODELLING 95
2.7 PRODUCT TYPE LIFELINE CURVE 95
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 96
2.9 DBMR MARKET POSITION GRID 97
2.10 MARKET APPLICATION COVERAGE GRID 98
2.11 VENDOR SHARE ANALYSIS 99
2.12 SECONDARY SOURCES 100
2.13 ASSUMPTIONS 100
3 EXECUTIVE SUMMARY 101
4 PREMIUM INSIGHTS 104
4.1 PESTEL ANALYSIS 105
4.2 PORTER'S 5 FORCES 106
5 INDUSTRY INSIGHTS 107
6 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, REGULATIONS 108
7 MARKET OVERVIEW 110
7.1 DRIVERS 112
7.1.1 INCREASED GROWTH IN PREVALENCE OF NON-HODGKIN LYMPHOMA 112
7.1.2 INCREASE IN AWARENESS REGARDING NON-HODGKIN LYMPHOMA 112
7.1.3 ADVANCEMENT IN ARTIFICIAL INTELLIGENCE IN DIAGNOSIS OF NON-HODGKIN LYMPHOMA 112
7.1.4 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UP 113
7.2 RESTRAINTS 113
7.2.1 LACK OF AVAILABILITY OF TRAINED AND SKILLED MEDICAL PROFESSIONALS 113
7.2.2 STRINGENT REGULATIONS AND GUIDELINES FOR DIFFERENT TREATMENTS AND DIAGNOSIS 114
7.3 OPPORTUNITIES 115
7.3.1 TECHNICAL ADVANCEMENTS IN CANCER DIAGNOSIS 115
7.3.2 INCREASING HEALTHCARE EXPENDITURE IN CANCER R&D 115
7.3.3 GROWING INITIATIVES BY GOVERNMENT AND KEY PLAYERS 115
7.4 CHALLENGES 116
7.4.1 LACK OF EARLY DIAGNOSTIC AWARENESS AMONG PEOPLE 116
7.4.2 HIGH DIAGNOSTIC COST AND FEAR OF TREATMENT 116
7.4.3 COMMON MISDIAGNOSIS OF NON-HODGKIN LYMPHOMA (NHL) 117
8 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TEST TYPE 118
8.1 OVERVIEW 119
8.2 IMAGING 122
8.2.1 COMPUTED TOMOGRAPHY (CT) 123
8.2.2 CHEST X-RAY 123
8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 123
8.2.4 ULTRASOUND 123
8.2.5 POSITRON EMISSION TOMOGRAPHY (PET) 123
8.3 BIOPSY 123
8.3.1 EXCISIONAL OR INCISIONAL BIOPSY 124
8.3.2 CORE NEEDLE BIOPSY 124
8.4 IMMUNOHISTOCHEMISTRY 124
8.5 BIOMARKER TEST 125
8.5.1 BETA 2-M 126
8.5.2 LDH 126
8.5.3 CA-125 126
8.5.4 TP53 126
8.5.5 NPM1 127
8.5.6 OTHERS 127
8.6 GENETIC TEST 127
8.7 CYTOGENETICS 127
8.8 LUMBAR PUNCTURE (SPINAL TAP) 128
8.9 BLOOD TEST 129
8.10 CYTOCHEMISTRY 129
8.11 OTHERS 130
9 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TUMOR TYPE 131
9.1 OVERVIEW 132
9.2 AGGRESSIVE LYMPHOMAS 134
9.2.1 DIFFUSE LARGE B CELL LYMPHOMA 135
9.2.1.1 INSTRUMENT BASED PRODUCTS 136
9.2.1.2 PLATFORM BASED PRODUCTS 136
9.2.1.3 KITS AND REAGENTS 136
9.2.1.4 OTHER CONSUMABLES 136
9.2.2 ANAPLASTIC LARGE-CELL LYMPHOMA 136
9.2.2.1 INSTRUMENT BASED PRODUCTS 137
9.2.2.2 PLATFORM BASED PRODUCTS 137
9.2.2.3 KITS AND REAGENTS 137
9.2.2.4 OTHER CONSUMABLES 137
9.2.3 MANTLE CELL LYMPHOMA 137
9.2.3.1 INSTRUMENT BASED PRODUCTS 138
9.2.3.2 PLATFORM BASED PRODUCTS 138
9.2.3.3 KITS AND REAGENTS 138
9.2.3.4 OTHER CONSUMABLES 138
9.2.4 PERIPHERAL T-CELL LYMPHOMA 138
9.2.4.1 INSTRUMENT BASED PRODUCTS 139
9.2.4.2 PLATFORM BASED PRODUCTS 139
9.2.4.3 KITS AND REAGENTS 139
9.2.4.4 OTHER CONSUMABLES 139
9.2.5 LYMPHOBLASTIC LYMPHOMA 139
9.2.5.1 INSTRUMENT BASED PRODUCTS 140
9.2.5.2 PLATFORM BASED PRODUCTS 140
9.2.5.3 KITS AND REAGENTS 140
9.2.5.4 OTHER CONSUMABLES 140
9.2.6 BURKITT LYMPHOMA 140
9.2.6.1 INSTRUMENT BASED PRODUCTS 141
9.2.6.2 PLATFORM BASED PRODUCTS 141
9.2.6.3 KITS AND REAGENTS 141
9.2.6.4 OTHER CONSUMABLES 141
9.3 INDOLENT LYMPHOMAS 141
9.3.1 FOLLICULAR LYMPHOMA 142
9.3.1.1 INSTRUMENT BASED PRODUCTS 143
9.3.1.2 PLATFORM BASED PRODUCTS 143
9.3.1.3 KITS AND REAGENTS 143
9.3.1.4 OTHER CONSUMABLES 143
9.3.2 CUTANEOUS T-CELL LYMPHOMA 143
9.3.2.1 INSTRUMENT BASED PRODUCTS 144
9.3.2.2 PLATFORM BASED PRODUCTS 144
9.3.2.3 KITS AND REAGENTS 144
9.3.2.4 OTHER CONSUMABLES 144
9.3.3 MARGINAL ZONE B CELL LYMPHOMA 144
9.3.3.1 INSTRUMENT BASED PRODUCTS 145
9.3.3.2 PLATFORM BASED PRODUCTS 145
9.3.3.3 KITS AND REAGENTS 145
9.3.3.4 OTHER CONSUMABLES 145
9.3.4 LYMPHOPLASMACYTIC LYMPHOMA 145
9.3.4.1 INSTRUMENT BASED PRODUCTS 146
9.3.4.2 PLATFORM BASED PRODUCTS 146
9.3.4.3 KITS AND REAGENTS 146
9.3.4.4 OTHER CONSUMABLES 146
9.3.5 SMALL-CELL LYMPHOCYTIC LYMPHOMA 146
9.3.5.1 INSTRUMENT BASED PRODUCTS 147
9.3.5.2 PLATFORM BASED PRODUCTS 147
9.3.5.3 KITS AND REAGENTS 147
9.3.5.4 OTHER CONSUMABLES 147
10 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY APPLICATION 148
10.1 OVERVIEW 149
10.2 SCREENING 151
10.2.1 INSTRUMENT BASED PRODUCTS 152
10.2.2 PLATFORM BASED PRODUCTS 152
10.2.3 KITS AND REAGENTS 153
10.2.4 OTHER CONSUMABLES 153
10.3 DIAGNOSTIC AND PREDICTIVE 153
10.3.1 INSTRUMENT BASED PRODUCTS 154
10.3.2 PLATFORM BASED PRODUCTS 154
10.3.3 KITS AND REAGENTS 154
10.3.4 OTHER CONSUMABLES 154
10.4 PROGNOSTIC 154
10.4.1 INSTRUMENT BASED PRODUCTS 155
10.4.2 PLATFORM BASED PRODUCTS 155
10.4.3 KITS AND REAGENTS 155
10.4.4 OTHER CONSUMABLES 156
10.5 RESEARCH 156
10.5.1 INSTRUMENT BASED PRODUCTS 157
10.5.2 PLATFORM BASED PRODUCTS 157
10.5.3 KITS AND REAGENTS 157
10.5.4 OTHER CONSUMABLES 157
11 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE 158
11.1 OVERVIEW 159
11.2 STAGE IV 161
11.3 STAGE I 162
11.4 STAGE III 163
11.5 STAGE II 164
11.6 STAGE 0 165
12 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TECHNOLOGY 166
12.1 OVERVIEW 167
12.2 FLUORESCENT IN SITU HYBRIDIZATION 169
12.3 NEXT GENERATION SEQUENCING 170
12.4 FLUORIMMUNOASSAY 171
12.5 COMPARATIVE GENOMIC HYBRIDIZATION 172
12.6 IMMUNOHISTOLOCHEMICAL 172
12.7 OTHER 173
13 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY PRODUCT 174
13.1 OVERVIEW 175
13.2 INSTRUMENT BASED PRODUCTS 177
13.2.1 IMAGING 178
13.2.2 BIOPSY 178
13.3 PLATFORM BASED PRODUCTS 179
13.3.1 NEXT-GENERATION SEQUENCING 180
13.3.2 MICROARRAYS 180
13.3.3 PCR 180
13.3.4 OTHERS 180
13.4 KITS AND REAGENTS 180
13.4.1 NON-HODGKIN LYMPHOMA PANELS 181
13.4.2 IMMUNOHISTOCHEMISTRY STAINS 181
13.4.3 OTHERS 181
13.5 OTHER CONSUMABLES 182
14 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY END USER 183
14.1 OVERVIEW 184
14.2 HOSPITALS 186
14.3 DIAGNOSTIC CENTERS 187
14.4 CANCER RESEARCH CENTERS 188
14.5 ACADEMIC INSTITUTES 189
14.6 AMBULATORY SURGICAL CENTERS 189
14.7 OTHERS 190
15 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 191
15.1 OVERVIEW 192
15.2 DIRECT TENDER 194
15.3 RETAIL SALES 195
15.4 OTHERS 196
16 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION 197
16.1 NORTH AMERICA 198
16.1.1 U.S. 216
16.1.2 CANADA 228
16.1.3 MEXICO 240
17 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 252
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 252
18 SWOT ANALYSIS 253
19 NORTH AMERICA NON-HODKIN LYMPHOMA DIAGNOSTICS MARKET 254
19.1 CANON MEDICAL SYSTEMS CORPORATION 254
19.1.1 COMPANY SNAPSHOT 254
19.1.2 REVENUE ANALYSIS 254
19.1.3 COMPANY SHARE ANALYSIS 255
19.1.4 PRODUCT PORTFOLIO 255
19.1.5 RECENT DEVELOPMENT 255
19.2 KONINKLIJKE PHILIPS N.V. 256
19.2.1 COMPANY SNAPSHOT 256
19.2.2 REVENUE ANALYSIS 256
19.2.3 COMPANY SHARE ANALYSIS 257
19.2.4 PRODUCT PORTFOLIO 257
19.2.5 RECENT DEVELOPMENTS 257
19.3 SIEMENS HEALTHCARE GMBH 258
19.3.1 COMPANY SNAPSHOT 258
19.3.2 REVENUE ANALYSIS 258
19.3.3 COMPANY SHARE ANALYSIS 259
19.3.4 PRODUCT PORTFOLIO 259
19.3.5 RECENT DEVELOPMENT 260
19.4 DANAHER. 261
19.4.1 COMPANY SNAPSHOT 261
19.4.2 REVENUE ANALYSIS 261
19.4.3 COMPANY SHARE ANALYSIS 262
19.4.4 PRODUCT PORTFOLIO 262
19.4.5 RECENT DEVELOPMENTS 263
19.5 BIO-RAD LABORATORIES, INC. 264
19.5.1 COMPANY SNAPSHOT 264
19.5.2 REVENUE ANALYSIS 264
19.5.3 COMPANY SHARE ANALYSIS 265
19.5.4 PRODUCT PORTFOLIO 265
19.5.5 RECENT DEVELOPMENT 265
19.6 AGILENT TECHNOLOGIES, INC. 266
19.6.1 COMPANY PROFILE 266
19.6.2 REVENUE ANALYSIS 266
19.6.3 PRODUCT PORTFOLIO 267
19.6.4 RECENT DEVELOPMENT 267
19.7 CENTOGENE N.V. 268
19.7.1 COMPANY SNAPSHOT 268
19.7.2 PRODUCT PORTFOLIO 268
19.7.3 RECENT DEVELOPMENT 268
19.8 F. HOFFMANN- LA ROCHE LTD 269
19.8.1 COMPANY SNAPSHOT 269
19.8.2 REVENUE ANALYSIS 269
19.8.3 PRODUCT PORTFOLIO 270
19.8.4 RECENT DEVELOPMENTS 270
19.9 GENERAL ELECTRIC COMPANY 271
19.9.1 COMPANY SNAPSHOT 271
19.9.2 REVENUE ANALYSIS 271
19.9.3 PRODUCT PORTFOLIO 272
19.9.4 RECENT DEVELOPMENTS 272

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（診断薬）の最新刊レポート

Data Bridge Market Research 社の最新刊レポート

本レポートと同じKEY WORD（diagnostics）の最新刊レポート


よくあるご質問


Data Bridge Market Research社はどのような調査会社ですか?


データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/09/09　10:27

143.78 円

159.73 円

191.51 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.